Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
about
An economic model of long-term use of celecoxib in patients with osteoarthritisA comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an exampleCost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.Economic evaluation of treatment strategies in gastroenterology.Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study.Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.Nanofibers used for the delivery of analgesics.Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information.Inadequate prevention of NSAID-induced gastrointestinal events.Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
P2860
Q28218005-83644F43-68C7-40BD-95BC-B7F2FDD59F5DQ28472098-98809C90-9E4F-42BE-8679-39B9E21ED93AQ34384075-6BDA058D-9E62-48EB-AF2A-BE28F5A51BB1Q35814862-3150CD5F-560C-46BC-AB92-16BB2078700DQ36266521-F4AD1256-FC35-4941-8275-D2F9A5DC2F53Q37129605-57B2FCB8-CC7F-4ABA-B0CE-768682E4ABF6Q38042714-A793622C-6B03-4BF3-9CA4-417058943D99Q38529529-1B0EF172-F44D-4CC1-8371-48B7C64C9D34Q43219102-C39CB54F-6F76-45DF-B9E8-5E3F0FB1E0DEQ44805672-7CE50DCA-78AB-4A11-9E44-1B01A433E24EQ44808671-E69E96A1-3E5C-4817-925E-F05F37792C88Q45347178-B20E5FC9-0243-476C-985E-6499D18DD445Q46051343-27599C20-9563-472F-AC2D-8A65FB97C866Q46150327-1266BE6E-591B-4F8C-AF2D-AC72AC6F4EB8Q46447275-D66936DA-9823-4742-A04F-407707BF8B60
P2860
Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@en
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@nl
type
label
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@en
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@nl
prefLabel
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@en
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@nl
P1476
Prevention of complicated ulce ...... n cost-effectiveness analysis.
@en
P2093
Hashem B El-Serag
Peter Richardson
P304
P356
10.1001/ARCHINTE.162.18.2105
P407
P577
2002-10-01T00:00:00Z